Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants
about
Diabetes Drugs and Cardiovascular SafetyDipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studiesDipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three StudiesNew perspectives on exploitation of incretin peptides for the treatment of diabetes and related disordersCurrent perspectives on cardiovascular outcome trials in diabetesRecent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsSAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.The nonglycemic actions of dipeptidyl peptidase-4 inhibitorsPleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemIncretin-based therapies in prediabetes: Current evidence and future perspectivesEffectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data.Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular eventsIncreased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database.Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells.Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus.Plasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients.Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort StudyCardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.GLP-1: benefits beyond pancreas.A review of gliptins for 2014.DPP-4 inhibitors: focus on safety.Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability.Managing comorbidities in patients with chronic heart failure: first, do no harm.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.Rosemary Extract as a Potential Anti-Hyperglycemic Agent: Current Evidence and Future Perspectives.An update on drug-induced arthritis.Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.Cardiovascular effects of anti-diabetes drugs.Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications.Clinical outcomes, not clinical utility, should be the major consideration for saxagliptin with or without metformin.A review on cardiovascular effects of newer hypoglycaemic medications.Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials.Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Databas
P2860
Q26746085-DEF3A234-F730-4CBC-9957-760DD1CBC32CQ26765047-BC1D518E-FDB5-45F0-AE31-A0508965B4D2Q26777177-ECB7969E-7509-48EF-B12A-7F6755045CB1Q26777654-5BA562A7-A870-4F1B-BEB7-FB6C1578F60AQ28066006-5615A4E7-6ED4-4303-8FDA-02952E2FC06BQ28081569-E1B6ECF1-F317-48C6-B508-4FDEE8F5FD12Q30238791-A0C6779A-E444-4D8E-8F13-58475ACDE675Q30846870-1E18D848-8293-4954-9F19-1D0A38AB9A52Q33660548-2D096E49-F1D8-4436-936E-C362E8206585Q33775785-00039243-1184-4E15-AA04-DDCD89073FA2Q34029715-3E59E3E6-E715-4B61-9450-B59F48F1AC28Q34062829-AB77D7E8-17AD-4657-8B55-CA30E1BD99D5Q34699191-0328A67D-741A-472F-A1F8-4D55F3C3459AQ34726395-5838D0A6-14AB-4C8E-8B62-A8DDBE8F9E51Q35736564-444E7909-FBA4-40BE-BB2C-C0777339AF37Q35790650-572A38AE-83ED-4F36-9740-C62776BB1994Q36687153-402AC3B0-5ACC-46F7-9958-4932E581BBF9Q37337371-90614470-D399-477D-A0F6-D98CB3ACD580Q37522403-B342F933-7E7D-473B-8D29-4D4FD20B7DCBQ37527438-0C7DADAB-F09D-4506-BBAF-C99F3BAF5D5EQ37562586-2866CAFE-5F6F-416E-8878-1395C99A4B67Q38238288-BCA52FA9-2AB3-400C-B4A2-023C067288D7Q38266290-F67F0342-B3C5-4AEA-A942-2719C5A359B6Q38285608-D56172B6-8D76-477F-97A9-5E728D766A88Q38371242-D27472C7-4565-4D16-9E68-597BE61B5B91Q38389314-8E8C2211-2E02-4E7E-94AD-DBA5099FA91DQ38401198-9C537711-1013-4C76-BB10-DCF96FF3C41AQ38402807-FB0B5FBB-7548-4E26-A0B6-A941EB67112CQ38410742-C1FF8749-A19B-428C-B60C-548C582CC669Q38586898-71697E1F-2BE7-4F2E-8C00-BD4E23E5826AQ38634459-64F4A512-0C24-4732-8E7E-F3E12A664D75Q38783509-03CFBD0C-FB81-481E-8C04-25AD9A608EDBQ38836416-3AC68673-3068-4521-A080-C9A0DC4AA341Q38857056-E1F7F798-8889-4227-8C1A-207011E6485BQ38901098-086315EF-2D4B-461B-A7F0-38A489F6FE67Q38959523-E9AEB017-2241-4BFA-A46A-11E8F197A258Q39328296-351FB881-533C-4E6A-B781-6A6637B1DB88Q39870068-F651A48B-EC42-41B4-A5AC-E37775BAF232Q40651201-BA32FD5D-ABC8-4CDE-996D-275733C3D9C7Q40795716-7BBBAA13-ACF7-44BF-939B-99C725A719F1
P2860
Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Dipeptidyl peptidase-4 inhibit ...... rials with 55,141 participants
@ast
Dipeptidyl peptidase-4 inhibit ...... rials with 55,141 participants
@en
Dipeptidyl peptidase-4 inhibit ...... rials with 55,141 participants
@nl
type
label
Dipeptidyl peptidase-4 inhibit ...... rials with 55,141 participants
@ast
Dipeptidyl peptidase-4 inhibit ...... rials with 55,141 participants
@en
Dipeptidyl peptidase-4 inhibit ...... rials with 55,141 participants
@nl
prefLabel
Dipeptidyl peptidase-4 inhibit ...... rials with 55,141 participants
@ast
Dipeptidyl peptidase-4 inhibit ...... rials with 55,141 participants
@en
Dipeptidyl peptidase-4 inhibit ...... rials with 55,141 participants
@nl
P2860
P50
P3181
P356
P1476
Dipeptidyl peptidase-4 inhibit ...... rials with 55,141 participants
@en
P2093
Shiying Wu
P2860
P304
P3181
P356
10.1111/1755-5922.12075
P407
P577
2014-08-01T00:00:00Z